The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 25, 2025
Filed:
Mar. 28, 2024
Applicant:
Accent Therapeutics, Inc., Lexington, MA (US);
Inventors:
Matthew H. Daniels, Somerville, MA (US);
Kenneth W. Duncan, Westwood, MA (US);
Brian Andrew Sparling, Saugus, MA (US);
Andrew Stewart Tasker, Simi Valley, CA (US);
Gavin Whitlock, Lexington, MA (US);
Assignee:
ACCENT THERAPEUTICS, INC., Lexington, MA (US);
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/506 (2006.01); A61K 31/18 (2006.01); A61K 31/277 (2006.01); A61K 31/341 (2006.01); A61K 31/381 (2006.01); A61K 31/40 (2006.01); A61K 31/415 (2006.01); A61K 31/4164 (2006.01); A61K 31/437 (2006.01); A61K 31/4418 (2006.01); A61K 31/4436 (2006.01); A61K 31/4439 (2006.01); A61K 31/496 (2006.01); A61K 31/497 (2006.01); A61K 31/4985 (2006.01); A61K 31/5377 (2006.01); A61K 31/675 (2006.01); A61P 35/00 (2006.01); C07C 311/08 (2006.01); C07D 207/34 (2006.01); C07D 213/56 (2006.01); C07D 231/12 (2006.01); C07D 231/14 (2006.01); C07D 233/90 (2006.01); C07D 307/68 (2006.01); C07D 333/38 (2006.01); C07D 333/70 (2006.01); C07D 401/04 (2006.01); C07D 401/14 (2006.01); C07D 403/04 (2006.01); C07D 409/04 (2006.01); C07D 409/14 (2006.01); C07D 413/14 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01); C07F 9/6558 (2006.01);
U.S. Cl.
CPC ...
A61K 31/506 (2013.01); A61K 31/18 (2013.01); A61K 31/277 (2013.01); A61K 31/341 (2013.01); A61K 31/381 (2013.01); A61K 31/40 (2013.01); A61K 31/415 (2013.01); A61K 31/4164 (2013.01); A61K 31/437 (2013.01); A61K 31/4418 (2013.01); A61K 31/4436 (2013.01); A61K 31/4439 (2013.01); A61K 31/496 (2013.01); A61K 31/497 (2013.01); A61K 31/4985 (2013.01); A61K 31/5377 (2013.01); A61K 31/675 (2013.01); A61P 35/00 (2018.01); C07C 311/08 (2013.01); C07D 207/34 (2013.01); C07D 213/56 (2013.01); C07D 231/12 (2013.01); C07D 231/14 (2013.01); C07D 233/90 (2013.01); C07D 307/68 (2013.01); C07D 333/38 (2013.01); C07D 333/70 (2013.01); C07D 401/04 (2013.01); C07D 401/14 (2013.01); C07D 403/04 (2013.01); C07D 409/04 (2013.01); C07D 409/14 (2013.01); C07D 413/14 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01); C07F 9/65583 (2013.01);
Abstract
Provided are compounds of the Formula (IVB): or pharmaceutically acceptable salts thereof, which are useful for the inhibition of DHX9 and in the treatment of a variety of DHX9 mediated conditions or diseases, such as cancer.